Trade Report: The Bbva Compass Bancshares Inc. Sold shares of Celgene Corp. (CELG)

The Bbva Compass Bancshares Inc. Sold shares of Celgene Corp. (CELG)

Bbva Compass Bancshares Inc. lowered its stake in shares of Celgene Corp. (NASDAQ:CELG) by 2.8% during the second quarter, Holdings Channel reports. The institutional investor owned 25,582 shares of the biopharmaceutical company’s stock after selling 749 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Celgene Corp. were worth $2,523,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Ropes Wealth Advisors LLC increased its stake in shares of Celgene Corp. by 0.9% in the first quarter. Ropes Wealth Advisors LLC now owns 1,477 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 13 shares in the last quarter. Kings Point Capital Management increased its stake in shares of Celgene Corp. by 1.7% in the first quarter. Kings Point Capital Management now owns 1,316 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 22 shares in the last quarter. Pitcairn Co. increased its stake in shares of Celgene Corp. by 0.8% in the second quarter. Pitcairn Co. now owns 4,948 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 38 shares in the last quarter. Meristem LLP increased its stake in shares of Celgene Corp. by 1.7% in the second quarter. Meristem LLP now owns 2,391 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 40 shares in the last quarter. Finally, Signaturefd LLC increased its stake in shares of Celgene Corp. by 1.2% in the second quarter. Signaturefd LLC now owns 3,836 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 47 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Celgene Corp. (NASDAQ:CELG) traded up 1.38% on Monday, reaching $99.86. The company’s stock had a trading volume of 3,161,883 shares. The firm’s 50-day moving average price is $105.76 and its 200-day moving average price is $105.48. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $128.39. The stock has a market cap of $77.40 billion, a price-to-earnings ratio of 42.21 and a beta of 1.49.

Celgene Corp. (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.05. The business earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. The company’s quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.23 EPS. On average, equities analysts expect that Celgene Corp. will post $5.71 earnings per share for the current year.

Several equities research analysts recently issued reports on the company. Canaccord Genuity set a $156.00 price objective on Celgene Corp. and gave the stock a “buy” rating in a research note on Sunday, September 18th. BMO Capital Markets reissued an “outperform” rating and issued a $141.00 price objective on shares of Celgene Corp. in a research note on Monday. Jefferies Group reaffirmed a “buy” rating on shares of Celgene Corp. in a research note on Monday. Morgan Stanley reaffirmed a “hold” rating on shares of Celgene Corp. in a research note on Thursday, June 30th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $150.00 price target on shares of Celgene Corp. in a research note on Thursday, July 28th. Three equities research analysts have rated the stock with a hold rating and twenty-five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $136.46.

In other Celgene Corp. news, Director Richard W. Barker sold 20,000 shares of Celgene Corp. stock in a transaction that occurred on Friday, September 23rd. The shares were sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the transaction, the director now owns 31,332 shares of the company’s stock, valued at approximately $3,472,212.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael A. Friedman sold 56,116 shares of Celgene Corp. stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $103.66, for a total transaction of $5,816,984.56. Following the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $5,183,000. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Related posts

Leave a Comment